CTI Life Sciences
Investor profile
Venture capital
Deals
3
distinct rounds
Companies
3
backed
Active span
2022–2023
2 yrs
Total round €
€181M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- 3B Future Health Fund1
- adMare BioInnovations1
- Advent Life Sciences1
- Andera Partners1
- ATEM1
- Cambridge Innovation Capital1
- Crédit Agricole Création1
- EQT Life Sciences1
- Fonds de solidarité FTQ1
- Harrington Discovery Institute1
- Innobio 21
- Intermediate Capital Group1
- Kurma Partners1
- Mass General Brigham Ventures1
- Novateur Ventures1
- Novo Holdings1
- Omnes Capital1
- OrbiMed1
- Panacea Venture1
- Pontifax Funds1
- Relyens Innovation Santé/Turenne Capital1
- Schroders Capital1
- Sectoral Asset Management1
- Seventure Partners1
- Sofinnova Partners1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Amolyt Pharma | France | 1 | €129M |
| Domain Therapeutics | France | 1 | €40M |
| Epitopea | UK | 1 | €12M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Amolyt Pharma | Series C | €129M | 2023-01 |
| Domain Therapeutics | Series A | €40M | 2022-05 |
| Epitopea | Seed | €12M | 2022-04 |